Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Key facts

Sponsor

Sun Yat-sen University

Intervention

Camrelizumab combined GP chemotherapy(drug)

Enrollment

242 target

Eligibility

18 years · All sexes

Timeline

2024 – 2029

Study locations (1)

• SunYat-senU, Guangzhou, Guangdong, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06980038
  Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT07362979
  Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
  Sun Yat-sen University
• RECRUITINGNANCT06796270
  Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
  The Second Affiliated Hospital of Hainan Medical University
• RECRUITINGPHASE2NCT06059261
  Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
  Chongqing University Cancer Hospital
• RECRUITINGNCT07376603
  IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
  Qiaojuan Guo
• RECRUITINGPHASE3NCT07340515
  Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
  Man Hu
• RECRUITINGPHASE3NCT07328854
  40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
  Ming-Yuan Chen
• RECRUITINGNCT07232680
  Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy
  Cheng-En Hsieh

See all trials for Nasopharyngeal carcinoma →